N-CBZ-L-hydroxyproline | 209269-34-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-CBZ-L-hydroxyproline
• 英文别名: N-Cbz-3-hydroxyproline；(2S)-3-hydroxy-1-phenylmethoxycarbonylpyrrolidine-2-carboxylic acid
• CAS: 209269-34-1
• 化学式: C₁₃H₁₅NO₅
• 分子量: 265.266
• InChiKey: PXVPQILKAQMLKV-DTIOYNMSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  87.1
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-CBZ-L-hydroxyproline 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 以46%的产率得到Cbz-反式-4-羟基-L-脯氨醇
  参考文献：
  名称：

  Solid support for synthesis of 3'-tailed oligonucleotides

  摘要：

  固体支持物质用于寡核苷酸合成具有以下结构##STR1##其中CPG代表受控孔玻璃基质，波浪线代表碳链与受控孔玻璃基质中的NH基共价连接，X为2,2'-二甲氧基三苯甲基或H，R为烷基、芳基、芳基烷基、杂原子烷基或杂原子芳基。二甲氧基三苯甲基基团通过酸处理从固体支持物质中去除，然后在将第一个寡核苷酸单元的3'末端连接到与R基团相连的羟基功能后，通过传统合成器逐步构建寡核苷酸。

  公开号：

  US05419966A1
• 作为产物：
  描述：

  (R)-1-Benzenesulfonyl-2-(tert-butyl-dimethyl-silanyloxymethyl)-pyrrolidin-3-ol 在 吡啶 、 盐酸 、 甲醇 、 ruthenium trichloride 、 sodium periodate 、 sodium amalgam 、 六氟合硅酸 、 三乙胺 作用下， 以 四氯化碳 、 乙醇 、 二氯甲烷 、 乙腈 为溶剂， 反应 33.0h， 生成 N-CBZ-L-hydroxyproline
  参考文献：
  名称：

  Substrate specificity of human prolyl-4-hydroxylase

  摘要：

  Proline analogs (3-F, 3-Cl, 3-Br, 3,3-cyclopropyl, 3,3-methylene, 3-Me, and 4-Me) were synthesized, incorporated into CbzGlyPheXGlyOEt, and tested as substrate analogues/mechanistic probes for the human prolyl-4-hydroxylase catalyzed hydroxylation reaction. With the exception of the 3-fluoroproline containing peptide, none of these peptides were substrates for the enzyme. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00183-8

文献信息

• [EN] IAP INHIBITORS<br/>[FR] INHIBITEURS DE PROTÉINES D'APOPTOSE
  申请人：TETRALOGIC PHARMACEUTICAL CORP

  公开号：WO2009094287A1

  公开（公告）日：2009-07-30

  The present invention describes compounds of the following formula: processes for their preparation, pharmaceutical compositions containing them, and their use in therapy. The compounds of the present invention inhibit IAPs (inhibitors of apoptosis proteins) and thus are useful in the treatment of cancer, autoimmune diseases and other disorders where a defect in apoptosis is implicated.

  本发明描述了以下式的化合物：它们的制备方法，含有它们的药物组合物，以及它们在治疗中的应用。本发明的化合物抑制IAPs（凋亡抑制蛋白），因此在癌症、自身免疫疾病和其他凋亡缺陷相关疾病的治疗中具有用处。
• Dipeptidyl peptidase-IV inhibitors
  申请人：Hulin Bernard

  公开号：US20050234065A1

  公开（公告）日：2005-10-20

  The invention provides compounds of Formula (I) or prodrugs thereof, or pharmaceutically acceptable salts of said compounds or prodrugs, or solvates of said compounds, prodrugs or salts, wherein A, N, X and R 1 are as defined herein; pharmaceutical compositions thereof; and methods of using the pharmaceutical compositions for the treatment of diseases, including Type 2 diabetes, Type 1 diabetes, impaired glucose tolerance, hyperglycemia, metabolic syndrome (syndrome X and/or insulin resistance syndrome), glucosuria, metabolic acidosis, arthritis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, short stature due to growth hormone deficiency, infertility due to polycystic ovary syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome; short bowel syndrome; and the prevention of disease progression in Type 2 diabetes.

  该发明提供了Formula (I)的化合物或其前药，或者该化合物或前药的药用可接受盐，或者该化合物、前药或盐的溶剂化合物，其中A、N、X和R1如本文所定义；以及这些药物组合物；以及使用这些药物组合物治疗疾病的方法，包括2型糖尿病、1型糖尿病、糖耐量受损、高血糖、代谢综合征（综合征X和/或胰岛素抵抗综合征）、葡萄糖尿病、代谢性酸中毒、关节炎、白内障、糖尿病神经病、糖尿病肾病、糖尿病视网膜病、糖尿病心肌病、肥胖、由肥胖恶化的疾病、高血压、高脂血症、动脉粥样硬化、骨质疏松症、脆弱、骨质流失、骨折、急性冠状动脉综合征、生长激素缺乏引起的矮小症、多囊卵巢综合征引起的不孕症、焦虑、抑郁、失眠、慢性疲劳、癫痫、进食障碍、慢性疼痛、酒精成瘾、与肠道蠕动相关的疾病、溃疡、肠易激综合征、炎症性肠病；短肠综合征；以及预防2型糖尿病疾病进展。
• Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases
  申请人：Cottrell M. Kevin

  公开号：US20050137140A1

  公开（公告）日：2005-06-23

  The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.

  本发明涉及化合物I的公式：或其药学上可接受的盐或混合物，其抑制丝氨酸蛋白酶活性，特别是乙型肝炎病毒NS3-NS4A蛋白酶的活性。因此，它们通过干扰乙型肝炎病毒的生命周期而发挥作用，并且还可用作抗病毒剂。本发明还涉及包含这些化合物的组合物，无论是用于体外使用还是用于给患有HCV感染的患者的治疗，以及制备这些化合物的过程。本发明还涉及通过给予含有本发明化合物的组合物来治疗患有HCV感染的患者的方法。本发明还涉及制备这些化合物的过程。
• Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
  申请人：Cottrell M. Kevin

  公开号：US20070161789A1

  公开（公告）日：2007-07-12

  The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.

  本发明涉及式I的化合物：或其药学上可接受的盐或混合物，其抑制丝氨酸蛋白酶活性，特别是丝氨酸蛋白酶NS3-NS4A的活性。因此，它们通过干扰丙型肝炎病毒的生命周期而起作用，并且也可用作抗病毒剂。本发明还涉及包含这些化合物的组合物，无论是用于外体使用还是用于治疗患有HCV感染的患者的给药，以及制备这些化合物的过程。本发明还涉及通过给予本发明的化合物组成物来治疗患者的HCV感染的方法。本发明还涉及制备这些化合物的过程。
• IAP INHIBITORS
  申请人：Condon Stephen M.

  公开号：US20110288116A1

  公开（公告）日：2011-11-24

  The present invention describes compounds of the following formula: processes for their preparation, pharmaceutical compositions containing them, and their use in therapy. The compounds of the present invention inhibit IAPs (inhibitors of apoptosis proteins) and thus are useful in the treatment of cancer, autoimmune diseases and other disorders where a defect in apoptosis is implicated.

  本发明描述了以下式子的化合物：它们的制备过程、含有它们的药物组合物以及它们在治疗中的应用。本发明的化合物抑制IAPs（凋亡抑制蛋白），因此在治疗癌症、自身免疫性疾病和其他涉及凋亡缺陷的疾病中很有用。